{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:12:45Z","timestamp":1793373165950,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for patients with hematologic malignancies, but the limited availability of HLA-matched sibling donors necessitates alternative graft sources. Haploidentical donors (HIDs) and double-unit umbilical cord blood (DUCB) are two widely used alternatives, yet direct comparisons of their clinical outcomes remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective single-center study of 97 patients with hematologic malignancies who underwent HSCT between August 2014 and May 2024. Patients received either HID transplantation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200957) or DUCB transplantation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200940). Hematopoietic recovery, graft-versus-host disease (GVHD), and long-term survival outcomes were assessed using cumulative incidence and Kaplan\u2013Meier analyses, with multivariate Cox regression applied to identify prognostic factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      HID recipients achieved significantly faster neutrophil (median: 14.00 vs. 22.50 days) and platelet recovery (median: 15.00 vs. 44.50 days) than DUCB recipients (both\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). The incidence of grade II\u2013IV acute GVHD (16.80% vs. 47.70%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and chronic GVHD (10.30% vs. 28.60%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.033) was lower in the HID group, although severe grade III\u2013IV aGVHD rates were comparable (13.00% vs. 23.90%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.160). Five-year overall survival (56.70% HID vs. 48.90% DUCB,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.573), relapse-free survival (76.60% vs. 89.70%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.210), GVHD-free relapse-free survival (48.00% vs. 46.30%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.410), and non-relapse mortality (NRM) (35.40% vs. 47.00%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.188) did not differ significantly between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both HID and DUCB transplantation are viable alternatives in the absence of an HLA-matched sibling donor. However, HID transplantation offers faster hematopoietic recovery and a reduced GVHD burden, which may provide practical clinical advantages when donor availability permits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16221-w","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T01:16:08Z","timestamp":1779412568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Haploidentical donor versus double-unit cord blood transplantation in hematologic malignancies: comparative survival and graft-versus-host disease outcomes from a decade of real-world experience"],"prefix":"10.1186","volume":"26","author":[{"given":"Rui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siguo","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangbo","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"1","key":"16221_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bbmt.2015.11.001","volume":"22","author":"J Apperley","year":"2016","unstructured":"Apperley J, et al. Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. Biol Blood Marrow Transpl. 2016;22(1):23\u20136.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"16221_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00277-019-03870-0","volume":"99","author":"A Esquirol","year":"2020","unstructured":"Esquirol A, et al. When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (thiotepa-busulfan-fludarabine). Ann Hematol. 2020;99(1):157\u201365.","journal-title":"Ann Hematol"},{"issue":"1","key":"16221_CR3","doi-asserted-by":"publisher","first-page":"2338300","DOI":"10.1080\/16078454.2024.2338300","volume":"29","author":"C Graham","year":"2024","unstructured":"Graham C, Litzow M. The use of haploidentical stem cell transplant as an alternative donor source in patients with decreased access to matched unrelated donors. Hematology. 2024;29(1):2338300.","journal-title":"Hematology"},{"issue":"1","key":"16221_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-021-01065-7","volume":"14","author":"A Nagler","year":"2021","unstructured":"Nagler A, et al. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. J Hematol Oncol. 2021;14(1):53.","journal-title":"J Hematol Oncol"},{"key":"16221_CR5","doi-asserted-by":"publisher","first-page":"963689724127040","DOI":"10.1177\/09636897241270401","volume":"33","author":"Z Gu","year":"2024","unstructured":"Gu Z, et al. Similar Survival But Less Chronic GVHD in Antithymocyte Globulin-Based Myeloablative Haploidentical Transplant Compared With Matched Sibling Transplant for Adult T-cell Acute Lymphoblastic Leukemia\/Lymphoma. Cell Transpl. 2024;33:9636897241270401.","journal-title":"Cell Transpl"},{"issue":"12","key":"16221_CR6","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1182\/bloodadvances.2019000050","volume":"3","author":"A Rashidi","year":"2019","unstructured":"Rashidi A, et al. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019;3(12):1826\u201336.","journal-title":"Blood Adv"},{"issue":"1","key":"16221_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-021-01094-2","volume":"14","author":"J Sanz","year":"2021","unstructured":"Sanz J, et al. Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. J Hematol Oncol. 2021;14(1):84.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"16221_CR8","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3324\/haematol.2015.127787","volume":"100","author":"B Oran","year":"2015","unstructured":"Oran B, et al. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica. 2015;100(10):1361\u201370.","journal-title":"Haematologica"},{"issue":"6","key":"16221_CR9","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.bbmt.2014.02.020","volume":"20","author":"D Weisdorf","year":"2014","unstructured":"Weisdorf D, et al. Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis. Biol Blood Marrow Transpl. 2014;20(6):816\u201322.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"16221_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.bbmt.2015.10.006","volume":"22","author":"S Terakura","year":"2016","unstructured":"Terakura S, et al. Comparison of Outcomes of 8\/8 and 7\/8 Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Cord Blood Transplantation in Adults with Acute Leukemia. Biol Blood Marrow Transpl. 2016;22(2):330\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"16221_CR11","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1158\/1078-0432.CCR-17-3622","volume":"24","author":"F Baron","year":"2018","unstructured":"Baron F, et al. Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen. Clin Cancer Res. 2018;24(12):2794\u2013803.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"16221_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41408-019-0204-x","volume":"9","author":"F Baron","year":"2019","unstructured":"Baron F, et al. Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT. Blood Cancer J. 2019;9(4):46.","journal-title":"Blood Cancer J"},{"issue":"3","key":"16221_CR13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1182\/blood.2020007535","volume":"137","author":"EJ Fuchs","year":"2021","unstructured":"Fuchs EJ, et al. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood. 2021;137(3):420\u20138.","journal-title":"Blood"},{"issue":"18","key":"16221_CR14","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa1405584","volume":"371","author":"JE Wagner Jr","year":"2014","unstructured":"Wagner JE Jr., et al. One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med. 2014;371(18):1685\u201394.","journal-title":"N Engl J Med"},{"issue":"6","key":"16221_CR15","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"16221_CR16","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945\u201356.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"16221_CR17","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41409-019-0722-y","volume":"55","author":"C Deteix","year":"2020","unstructured":"Deteix C, et al. Influence of alternative donor type on early survival after hematopoietic stem cell transplantation for acute myeloid leukemia lacking a sibling donor. Bone Marrow Transpl. 2020;55(4):749\u201357.","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"16221_CR18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.bbmt.2019.10.014","volume":"26","author":"J Sanz","year":"2020","unstructured":"Sanz J, et al. Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. Biol Blood Marrow Transpl. 2020;26(2):358\u201366.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"16221_CR19","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/s41409-022-01770-y","volume":"57","author":"J Sugita","year":"2022","unstructured":"Sugita J, et al. Comparable survival outcomes with haploidentical stem cell transplantation and cord blood transplantation. Bone Marrow Transpl. 2022;57(11):1681\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"16221_CR20","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s13312-025-00143-0","volume":"62","author":"D Mohapatra","year":"2025","unstructured":"Mohapatra D, et al. Outcome of Unrelated Umbilical Cord Blood Transplantation in India: A Less Explored Horizon. Indian Pediatr. 2025;62(12):881\u20135.","journal-title":"Indian Pediatr"},{"issue":"9","key":"16221_CR21","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.bbmt.2016.06.012","volume":"22","author":"K Ballen","year":"2016","unstructured":"Ballen K, et al. Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2016;22(9):1636\u201345.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"16221_CR22","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1182\/bloodadvances.2017014464","volume":"2","author":"N Bejanyan","year":"2018","unstructured":"Bejanyan N, et al. Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv. 2018;2(8):909\u201322.","journal-title":"Blood Adv"},{"issue":"8","key":"16221_CR23","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1182\/blood-2008-03-147041","volume":"113","author":"Y Atsuta","year":"2009","unstructured":"Atsuta Y, et al. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood. 2009;113(8):1631\u20138.","journal-title":"Blood"},{"issue":"1","key":"16221_CR24","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1186\/s13287-022-03186-3","volume":"13","author":"G Sun","year":"2022","unstructured":"Sun G, et al. Unrelated cord blood transplantation vs. HLA-matched sibling transplantation for adults with B-cell acute lymphoblastic leukemia in complete remission: superior OS for patients with long-term survival. Stem Cell Res Ther. 2022;13(1):500.","journal-title":"Stem Cell Res Ther"},{"issue":"9577","key":"16221_CR25","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1016\/S0140-6736(07)60915-5","volume":"369","author":"M Eapen","year":"2007","unstructured":"Eapen M, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007;369(9577):1947\u201354.","journal-title":"Lancet"},{"issue":"1","key":"16221_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.tmrv.2018.11.001","volume":"33","author":"L Wang","year":"2019","unstructured":"Wang L, et al. Single- Versus Double-Unit Umbilical Cord Blood Transplantation for Hematologic Diseases: A Systematic Review. Transfus Med Rev. 2019;33(1):51\u201360.","journal-title":"Transfus Med Rev"},{"issue":"2","key":"16221_CR27","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.1365-2141.2009.07883.x","volume":"147","author":"V Rocha","year":"2009","unstructured":"Rocha V, Gluckman E. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol. 2009;147(2):262\u201374.","journal-title":"Br J Haematol"},{"issue":"3","key":"16221_CR28","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1182\/blood-2004-07-2717","volume":"105","author":"JN Barker","year":"2005","unstructured":"Barker JN, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105(3):1343\u20137.","journal-title":"Blood"},{"key":"16221_CR29","doi-asserted-by":"publisher","first-page":"107517","DOI":"10.1016\/j.leukres.2024.107517","volume":"142","author":"PO Odutola","year":"2024","unstructured":"Odutola PO, Olorunyomi PO, Olorunyomi I. Single vs double umbilical cord blood transplantation in acute leukemia: Systematic review and meta-analysis. Leuk Res. 2024;142:107517.","journal-title":"Leuk Res"},{"issue":"3","key":"16221_CR30","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/bmt.2016.265","volume":"52","author":"YB Chen","year":"2017","unstructured":"Chen YB, et al. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. Bone Marrow Transpl. 2017;52(3):400\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"16221_CR31","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","volume":"6","author":"J Bola\u00f1os-Meade","year":"2019","unstructured":"Bola\u00f1os-Meade J, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019;6(3):e132\u201343.","journal-title":"Lancet Haematol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16221-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16221-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16221-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T23:47:49Z","timestamp":1784245669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16221-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16221"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16221-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board (IRB) of Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (Approval Number: XHEC-D-2025-006). All procedures involving human participants were conducted in accordance with IRB guidelines and the ethical principles outlined in the 1975 Declaration of Helsinki. Given the retrospective design of the study and the use of de-identified clinical data, the requirement for written informed consent was waived by the IRB.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable. No identifiable images or personal\/clinical details of participants that could compromise anonymity are presented in this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"864"}}